MetLife price target raised to $77 from $70 at Argus

Argus analyst Kevin Heal raised the firm’s price target on MetLife to $77 from $70 and keeps a Buy rating on the shares. The company’s Q2 results were slightly better than expected due to higher net investment income and premium growth in the U.S., the analyst tells investors in a research note. Argus adds that the firm has a positive view of MetLife’s business diversification, expansion through both M&A and organic growth, and commitment to shareholder returns.